• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Lundbeck cuts R&D as sales continue to rise

Lundbeck cuts R&D as sales continue to rise

August 10, 2011
CenterWatch Staff

Lundbeck saw its sales rise 9% in the second-quarter, continuing a run of revenue growth on the back of gains for Alzheimer's disease treatment Ebixa and a good showing for antidepressant Lexapro in the US, according to PharmaTimes.

Second-quarter operating profit rose 18% to 1.1 billion Danish kroner (about $211 million) on the back of sales up 13% at constant exchange rates to 4.1 billion kroner. The Danish drug maker now expects to post revenue at the top end of its 15.3-15.8 billion kroner forecast for 2011 as a whole.

Lundbeck's increased profitability of late has come in part on the back of a restructuring of its R&D operations and greater emphasis on outsourcing. That process looks set to continue, with the company saying it plans to reduce its permanent R&D headcount by 125-175, with most of the cuts coming from its Danish headquarters and an R&D facility in New Jersey, US.

"This is something we very much regret, but it is necessary in order to strengthen our long term growth prospects," commented chief executive Ulf Wiinberg.

Product sales continued with 'solid momentum', according to Lundbeck, with flagship antidepressant Cipralex  climbing 2% while the US version of the product, sold by Forest Laboratories as Lexapro , advanced 13%, thanks largely to price rises and increased bulk deliveries. The Alzheimer's disease drug Ebixa  climbed 16%, while sales of Azilect for Parkinson's disease rose 12%.

Lundbeck's newer products also made gains. Xenazine posted sales up 42%, while epilepsy drug Sabril showed an increase of 113%.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing